The Gene.Vision Team

The team behind the Gene.Vision website is headed by Professor Mariya Moosajee, Mr Peter Thomas and Dr Alex Yeong, supported by NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology and Retina UK.

Professor Mariya Moosajee

Professor Mariya Moosajee is a Consultant Ophthalmologist in Genetic Eye Disease at Moorfields Eye Hospital and Great Ormond Street Hospital for Children. She is a Professor of Molecular Ophthalmology at UCL Institute of Ophthalmology, and Group Leader of Ocular Genomics and Therapeutics at the Francis Crick Institute in London. Professor Moosajee’s current clinical focus is providing a genomic ophthalmology service for children and adults affected with pan-ocular genetic eye disease. She also leads an active research group and is focused on both clinical research, which involves detailed characterisation of patient’s clinical features and natural history studies to understand disease progression and define outcome metrics for clinical trials. In the laboratory, she is advancing our understanding of the molecular basis of ocular maldevelopment and inherited retinal dystrophies. Dr Moosajee is the joint President of the UK Eye Genetic Group, sits on the Education and Academic committees at the Royal College of Ophthalmologists, and is the President of Women in Vision UK.

Mr Peter Thomas

Peter is the Director of Digital Innovation and a Consultant Ophthalmologist at Moorfields Eye Hospital. Clinically, he specialises in paediatric ophthalmology and strabismus surgery. He has been involved in digital health for many years, and his main interest is in driving the digital transformation of eyecare in the UK. His work supports the creation of new models of care, for example the recent deployment of video consultations and home monitoring at Moorfields, that are more convenient and more available for patients. He sits on a number of national committees and boards to drive this process agenda across all of ophthalmology and in the NHS more generally. His current research with the Moorfields’ Digital/Clinical Lab involves the assessment of environmental impact of healthcare, and the creation and implementation of clinically helpful artificial intelligence solutions.

Dr Alex Yeong

Alex is a fifth-year ophthalmology specialist trainee based at the Royal Victoria Hospital in Belfast, Northern Ireland. He graduated from University of Dundee in 2013 and remained there for two years to complete his foundation training. He moved to Northern Ireland in 2015 to commence his ophthalmology training, but spent the past year at Moorfields Eye Hospital in London creating Gene.Vision. Alex has an interest in retinal diseases and has been involved in various research projects, including a Cochrane systematic review on a form of investigative treatment for age-related macular degeneration, he has contributed to the Textbook of Genomic Ophthalmology by writing the chapter on inherited retinal dystrophies under the supervision of Professors Mariya Moosajee and Andrew Webster. He also organised and run a research clinic in Belfast recruiting patients with nystagmus into the 100,000 Genomes Project, which subsequently piqued his interest in genetics and applied to help create the Gene.Vision website. Alex believes that patient care can be enhanced by bridging the gap between patients and healthcare professionals through sharing clinical information in a comprehensive and easily-understood manner. The Gene.Vision website is created around this core value.

Retina UK

Retina UK is a Retina UK is a CIO, Registered Charity Number: 1153851, working for people with inherited sight loss. They fund medical research to understand these complex conditions and speed up the search for treatments and provide information and support services to help more people lead fulfilling lives.

Retina UK has funded more than £16.5 million of research into inherited sight loss conditions in its 43-year history. For further information, please visit

The National Institute for Health Research (NIHR)

The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:

  • Funds, supports and delivers high quality research that benefits the NHS, public health and social care

  • Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research

  • Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future

  • Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services

  • Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.

This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care.